Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Osteosarcoma 1Esophageal Squamous Cell Carcinoma 1Bone Neoplasms 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × endostar protein × 1 year × Clear all
NCT06562673 2025-12-29

IACE-OS

Shanghai 6th People's Hospital

Phase 1/2 Completed
10 enrolled
Sarcoma

Bone Neoplasms, Osteosarcoma

NCT03086681 2025-07-29

ECWHCCFLACC

First Affiliated Hospital of Guangxi Medical University

Phase 2 Completed
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03797625 2025-07-23

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Fudan University

Phase 2 Completed
52 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡